Seeking participants with moderately to severely active ulcerative colitis
The purpose of this study is to see if guselkumab and golimumab when used together is safe and effective for treating participants with moderately to severely active ulcerative colitis (UC).
Guselkumab has been approved in the USA, the European Union (EU), Canada, and several other countries, including the Australian health authority (Therapeutic Goods Administration), for the treatment of adult patients with moderate to severe plaque psoriasis. In addition, guselkumab is being studied for the treatment of psoriatic arthritis, Crohn’s disease, and paediatric psoriasis.
Golimumab has been approved in countries worldwide, including the Therepeutic Goods Administration, for the indications of moderately to severely active ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Anticipated date the enrolment will close: December 2020
Who can take part
- 18 to 65 years of age
- Clinical diagnosis of ulcerative colitis
- Presence of stoma
- Presence of history of fistula
What is involved for you
Medical History, Physical Exam, Electrocardiogram (ECG), Weight, Height, Blood Pressure, Pulse, Heart Rate, Health Questionnaires, Blood Samples, Urine Test, Colonoscopy with biopsy collection, Stool Tests